Search clinical trials for: Cetuximab( erbitux®)

Total 16601 results

Bristol-Myers Squibb

Terminated

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Head and Neck Cancer | Neoplasm Metastasis | Colorectal Cancer

United States, Canada
King Faisal Specialist Hospital & Research Center

Completed

A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer

Colon Rectal Cancer Duke Stage Stageval

Saudi Arabia
Northwell Health

Terminated

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell | Carcinoma, Squamous Cell of Head and Neck

United States
University of California, San Diego
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Neoplasms | Nasopharynx Cancer | Head and Neck Squamous Cell Carcinoma | Oropharynx Cancer | Oral Cavity Cancer | Larynx Cancer | HNSCC | Hypopharynx Cancer | Cutaneous Squamous Cell Carcinoma | Lip SCC | Sinonasal Carcinoma

United States
Eli Lilly and Company

Completed

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Head and Neck Cancer

United States
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects (CHANCE)

Squamous Cell Carcinoma of the Head and Neck

China
TyrNovo Ltd.

Active, not recruiting

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Metastatic Solid Tumor | Colorectal Adenocarcinoma | Solid Tumor, Adult | Recurrent Solid Tumor

United States, Israel
Washington University School of Medicine
Novartis Pharmaceuticals

Completed

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (HNSCC)

Squamous Cell Carcinoma of the Head and Neck

United States
Eli Lilly and Company

Completed

Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

Colorectal Cancer

United States
University of Zurich

Completed

A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab

Laryngeal Cancer | Hypopharyngeal Cancer | Oropharyngeal Cancer

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

Colorectal Neoplasms

Korea, Republic of
K-Group, Beta, Inc., a wholly owned subsidiary...
Pfizer

Recruiting

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Spain, Australia, United States, Italy, Germany, Poland, Hungary
Nektar Therapeutics

Completed

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Cervical Cancer | Colorectal Cancer | Head and Neck Squamous Cell Carcinoma | Anal Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Merck KGaA, Darmstadt, Germany
Choice Pharma Taiwan

Completed

A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)

Carcinoma, Squamous Cell of Head and Neck

Taiwan
Martin Schuler, Prof. Dr. med.

Completed

Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (CEBIFOX)

Metastatic Colorectal Cancer

Germany
R-Pharm

Completed

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Colorectal Neoplasms

Spain, United States, France, Italy, Belgium, Czechia, United Kingdom, Russian Federation
Gilead Sciences
California Institute for Regenerative Medicine (CIRM)

Completed

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Colorectal Cancer | Solid Tumor

United States
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux® (GORTEC 2009-01)

Head and Neck Carcinoma

France
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
Heidelberg University
Merck KGaA, Darmstadt, Germany; University Hospital Heidelberg; Dept. of Radiation...

Unknown

Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy (ACCEPT)

Adenoid Cystic Carcinoma

Germany
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; National Comprehensive Cancer Network

Completed

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Squamous Cell Cancer | Head and Neck

United States
Centre Hospitalier of Chartres
Hospital of Chartres- France

Completed

Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR (CTXSCC)

Skin Diseases | Carcinoma, Squamous Cell

France
University Hospital, Ghent
Merck Sharp & Dohme LLC

Completed

A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. (MesoMab)

Cancer

Belgium, Netherlands
Eli Lilly and Company

Completed

A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

Mucinous Gastrointestinal Adenocarcinoma

United States
Eli Lilly and Company

Completed

Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma

Colorectal Neoplasms | Metastases, Neoplasm

United States
University of Heidelberg Medical Center
iOMEDICO AG

Completed

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) (HICARE)

Head and Neck Cancer

Germany
EMD Serono

Completed

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck Cancer

Czech Republic, France, United Kingdom, Belgium, Hungary, United States, Poland, Slovakia
Boehringer Ingelheim

Completed

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Neoplasms

France, Spain
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (PMS LAD SCCHN)

Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHN

India
Sun Yat-sen University
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy (ENCORE)

Nasopharyngeal Carcinoma

China
Eben Rosenthal
National Cancer Institute (NCI)

Terminated

Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery

Pancreatic Adenocarcinoma

United States
HiberCell, Inc.

Terminated

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer (PRIMUS)

Colorectal Cancer

United States, Puerto Rico, Germany, France
National University Hospital, Singapore

Unknown

Reactivating NK Cells in Treating Refractory Head and Neck Cancer (NKEXPHNC)

Nasopharyngeal Cancer | Head and Neck Squamous Cell Carcinoma

Singapore
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb

Terminated

Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

Lung Cancer

United States
Boneca Corporation

Terminated

Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer

Head and Neck Cancer

Finland
Institute of Oncology Ljubljana

Unknown

Treatment Selection According to Skin Reaction to Cetuximab

Head and Neck Cancer

Slovenia
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Advanced Solid Tumors

United States, France, Argentina, Australia, Belgium, Israel, Italy, Spain
Sichuan Cancer Hospital and Research Institute
Southwest Hospital, China; Affiliated Cancer Hospital & Institute of Guangzhou... and other collaborators

Unknown

Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Locally Advanced Thoracic Middle-lower Segment Esophageal Squamous Cell Carcinoma

China
Bristol-Myers Squibb

Completed

BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

Colorectal Cancer

United States, Canada, Netherlands
Robert Ferris
Bristol-Myers Squibb

Completed

ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy

Lung Cancer
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

Colorectal Neoplasms | Neoplasm | Metastases

United States, Canada
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); National Center for Research... and other collaborators

Completed

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Breast Cancer

United States
Eye & ENT Hospital of Fudan University

Recruiting

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Head and Neck Neoplasms | Metastatic Cancer | Recurrent Disease

China
Bayer

Completed

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

Neoplasms

United States
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

CRC

China
P.O. Witteveen
Merck KGaA, Darmstadt, Germany

Terminated

Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma (TRACC)

Resectable Esophageal Cancer

Netherlands
Georgetown University

Terminated

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

Head and Neck Squamous Cell Cancer

United States
University of Colorado, Denver

Completed

Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer

Recurrent Head and Neck Cancer

United States

Search clinical trials for: Cetuximab( erbitux®)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations